Tau-mediated iron export prevents ferroptotic damage after ischemic stroke

Molecular Psychiatry

Volumn 22, Issue 11, 2017, Pages 1520-1530

  Tuo, Q Z ^a,b,c   Lei, P ^b,c   Jackman, K A ^b   Li, X L ^b,c,d   Xiong, H ^c   Liuyang, Z Y ^a   Roisman, L ^e   Zhang, S T ^c   Ayton, S ^b   Wang, Q ^c   Crouch, P J ^e   Ganio, K ^b   Wang, X C ^a   Pei, L ^a   Adlard, P A ^b   Lu, Y M ^a   Cappai, R ^e   Wang, J Z ^a   Liu, R ^a   Bush, A I ^b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^c SICHUAN UNIVERSITY   (China)

^d HARBIN MEDICAL UNIVERSITY   (China)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PRECURSOR PROTEIN; CERULOPLASMIN; TAU PROTEIN; IRON; MAPT PROTEIN, MOUSE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ISCHEMIA; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME REPRESSION; FEMALE; FERROPTOSIS; IRON EXPORT; IRON TRANSPORT; LIMIT OF QUANTITATION; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; REPERFUSION INJURY; AGE; ANIMAL; BRAIN; BRAIN INJURY; CEREBRAL ARTERY DISEASE; CEREBROVASCULAR ACCIDENT; DISEASE MODEL; GENETICS; KNOCKOUT MOUSE; METABOLISM; NERVE CELL; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT;

AGE FACTORS; ANIMALS; BRAIN; BRAIN INJURIES; BRAIN ISCHEMIA; DISEASE MODELS, ANIMAL; INFARCTION, MIDDLE CEREBRAL ARTERY; IRON; MALE; MICE; MICE, KNOCKOUT; NEURONS; RATS; RATS, SPRAGUE-DAWLEY; REPERFUSION INJURY; STROKE; TAU PROTEINS;

EID: 85030530743     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2017.171     Document Type: Article

References (55)

1. Krishnamurthi RV, Feigin VL, Forouzanfar MH, Mensah GA, Connor M, Bennett DA et al. Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet Glob Health 2013; 1: e259-e281.
2. Langhorne P, Bernhardt J, Kwakkel G. Stroke rehabilitation. Lancet 2011; 377: 1693-1702.
3. Yeo LL, Paliwal P, Teoh HL, Seet RC, Chan BP, Liang S et al. Timing of recanalization after intravenous thrombolysis and functional outcomes after acute ischemic stroke. JAMA Neurol 2013; 70: 353-358.
4. Iadecola C, Anrather J. Stroke research at a crossroad: asking the brain for directions. Nat Neurosci 2011; 14: 1363-1368.
5. Kikuchi K, Tanaka E, Murai Y, Tancharoen S. Clinical trials in acute ischemic stroke. CNS Drugs 2014; 28: 929-938.
6. Foundation NS. The Economic Impact of Stroke in Australia, 2013.
7. DiNapoli VA, Huber JD, Houser K, Li X, Rosen CL. Early disruptions of the blood-brain barrier may contribute to exacerbated neuronal damage and prolonged functional recovery following stroke in aged rats. Neurobiol Aging 2008; 29: 753-764.
8. Jin K, Mao X, Xie L, Greenberg RB, Peng B, Moore A et al. Delayed transplantation of human neural precursor cells improves outcome from focal cerebral ischemia in aged rats. Aging Cell 2010; 9: 1076-1083.
9. Maynard CJ, Cappai R, Volitaskis I, Cherny RA, White AR, Beyreuther K et al. Overexpression of Alzheimer's disease amyloid-beta opposes the age-dependent elevations of brain copper and iron. J Biol Chem 2002; 277: 44670-44676.
10. Maynard CJ, Cappai R, Volitakis I, Cherny RA, Masters CL, Li QX et al. Gender and genetic background effects on brain metal levels in APP transgenic and normal mice: implications for Alzheimer beta-amyloid pathology. J Inorg Biochem 2006; 100: 952-962.
11. Lei P, Ayton S, Finkelstein DI, Spoerri L, Ciccotosto GD, Wright DK et al. Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat Med 2012; 18: 291-295.
12. Dietrich RB, Bradley WG Jr. Iron accumulation in the basal ganglia following severe ischemic-anoxic insults in children. Radiology 1988; 168: 203-206.
13. Lipscomb DC, Gorman LG, Traystman RJ, Hurn PD. Low molecular weight iron in cerebral ischemic acidosis in vivo. Stroke 1998; 29: 487-492; discussion 493.
14. Ding H, Yan CZ, Shi H, Zhao YS, Chang SY, Yu P et al. Hepcidin is involved in iron regulation in the ischemic brain. PLoS ONE 2011; 6: e25324.
15. Park UJ, Lee YA, Won SM, Lee JH, Kang SH, Springer JE et al. Blood-derived iron mediates free radical production and neuronal death in the hippocampal CA1 area following transient forebrain ischemia in rat. Acta Neuropathol 2011; 121: 459-473.
16. Fang KM, Cheng FC, Huang YL, Chung SY, Jian ZY, Lin MC. Trace element, antioxidant activity, and lipid peroxidation levels in brain cortex of gerbils after cerebral ischemic injury. Biol Trace Elem Res 2013; 152: 66-74.
17. Kondo Y, Asanuma M, Nishibayashi S, Iwata E, Ogawa N. Late-onset lipid peroxidation and neuronal cell death following transient forebrain ischemia in rat brain. Brain Res 1997; 772: 37-44.
18. Kondo Y, Ogawa N, Asanuma M, Ota Z, Mori A. Regional differences in late-onset iron deposition, ferritin, transferrin, astrocyte proliferation, and microglial activation after transient forebrain ischemia in rat brain. J Cerebr Blood Flow Metab 1995; 15: 216-226.
19. Castellanos M, Puig N, Carbonell T, Castillo J, Martinez J, Rama R et al. Iron intake increases infarct volume after permanent middle cerebral artery occlusion in rats. Brain Res 2002; 952: 1-6.
20. Patt A, Horesh IR, Berger EM, Harken AH, Repine JE. Iron depletion or chelation reduces ischemia/reperfusion-induced edema in gerbil brains. J Pediatr Surg 1990; 25: 224-227; discussion 227-228.
21. Davis S, Helfaer MA, Traystman RJ, Hurn PD. Parallel antioxidant and antiexcitotoxic therapy improves outcome after incomplete global cerebral ischemia in dogs. Stroke 1997; 28: 198-204; discussion 195-204.
22. Prass K, Ruscher K, Karsch M, Isaev N, Megow D, Priller J et al. Desferrioxamine induces delayed tolerance against cerebral ischemia in vivo and in vitro. J Cerebr Blood Flow Metab 2002; 22: 520-525.
23. Hanson LR, Roeytenberg A, Martinez PM, Coppes VG, Sweet DC, Rao RJ et al. Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke. J Pharmacol Exp Ther 2009; 330: 679-686.
24. Lei P, Ayton S, Finkelstein DI, Adlard PA, Masters CL, Bush AI. Tau protein: relevance to Parkinson's disease. Int J Biochem Cell Biol 2010; 42: 1775-1778.
25. Ma QL, Zuo X, Yang F, Ubeda OJ, Gant DJ, Alaverdyan M et al. Loss of MAP function leads to hippocampal synapse loss and deficits in the Morris Water Maze with aging. J Neurosci 2014; 34: 7124-7136.
26. Lei P, Ayton S, Moon S, Zhang Q, Volitakis I, Finkelstein DI et al. Motor and cognitive deficits in aged tau knockout mice in two background strains. Mol Neurodegener 2014; 9: 29.
27. Lei P, Ayton S, Appukuttan AT, Volitakis I, Adlard PA, Finkelstein DI et al. Clioquinol rescues Parkinsonism and dementia phenotypes of the tau knockout mouse. Neurobiol Dis 2015; 81: 168-175.
28. Lei P, Ayton S, Appukuttan AT, Moon S, Duce JA, Volitakis I et al. Lithium suppression of tau induces brain iron accumulation and neurodegeneration. Mol Psychiatry 2017; 22: 396-406.
29. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 2007; 316: 750-754.
30. Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 2010; 142: 387-397.
31. Li X, Lei P, Tuo Q, Ayton S, Li QX, Moon S et al. Enduring elevations of hippocampal amyloid precursor protein and iron are features of beta-amyloid toxicity and are mediated by tau. Neurotherapeutics 2015; 12: 862-873.
32. Dawson HN, Cantillana V, Jansen M, Wang HY, Vitek MP, Wilcock DM et al. Loss of tau elicits axonal degeneration in a mouse model of Alzheimer's disease. Neuroscience 2010; 169: 516-531.
33. Dawson HN, Ferreira A, Eyster MV, Ghoshal N, Binder LI, Vitek MP. Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice. J Cell Sci 2001; 114(Part 6): 1179-1187.
34. Huuskonen MT, Tuo QZ, Loppi S, Dhungana H, Korhonen P, McInnes LE et al. The copper bis(thiosemicarbazone) complex CuII(atsm) is protective against cerebral ischemia through modulation of the inflammatory milieu. Neurotherapeutics 2017; 14: 519-532.
35. Jackman K, Kunz A, Iadecola C. Modeling focal cerebral ischemia in vivo. Methods Mol Biol 2011; 793: 195-209.
36. Alkayed NJ, Harukuni I, Kimes AS, London ED, Traystman RJ, Hurn PD. Gender-linked brain injury in experimental stroke. Stroke 1998; 29: 159-165; discussion 166.
37. Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke 1986; 17: 472-476.
38. Lin TN, He YY, Wu G, Khan M, Hsu CY. Effect of brain edema on infarct volume in a focal cerebral ischemia model in rats. Stroke; a journal of cerebral circulation 1993; 24: 117-121.
39. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987; 325: 733-736.
40. Aricescu AR, Lu W, Jones EY. A time-and cost-efficient system for high-level protein production in mammalian cells. Acta Crystallogr D 2006; 62(Part 10): 1243-1250.
41. Wong BX, Ayton S, Lam LQ, Lei P, Adlard PA, Bush AI et al. A comparison of ceruloplasmin to biological polyanions in promoting the oxidation of Fe under physiologically relevant conditions. Biochim Biophys Acta 2014; 1840: 3299-3310.
42. Ayton S, Lei P, Duce JA, Wong BX, Sedjahtera A, Adlard PA et al. Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease. Ann Neurol 2013; 73: 554-559.
43. Duce JA, Tsatsanis A, Cater MA, James SA, Robb E, Wikhe K et al. Iron-export ferroxidase activity of ?-amyloid precursor protein is inhibited by zinc in Alzheimer's disease. Cell 2010; 142: 857-867.
44. Wong BX, Tsatsanis A, Lim LQ, Adlard PA, Bush AI, Duce JA. Beta-Amyloid precursor protein does not possess ferroxidase activity but does stabilize the cell surface ferrous iron exporter ferroportin. PLoS ONE 2014; 9: e114174.
45. McCarthy RC, Park YH, Kosman DJ. sAPP modulates iron efflux from brain microvascular endothelial cells by stabilizing the ferrous iron exporter ferroportin. EMBO Rep 2014; 15: 809-815.
46. Liu F, Schafer DP, McCullough LD. TTC, fluoro-Jade B and NeuN staining confirm evolving phases of infarction induced by middle cerebral artery occlusion. J Neurosci Methods 2009; 179: 1-8.
47. Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 2012; 149: 1060-1072.
48. Friedmann Angeli JP, Schneider M, Proneth B, Tyurina YY, Tyurin VA, Hammond VJ et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat Cell Biol 2014; 16: 1180-1191.
49. Conrad M, Angeli JP, Vandenabeele P, Stockwell BR. Regulated necrosis: disease relevance and therapeutic opportunities. Nat Rev Drug Discov 2016; 15: 348-366.
50. Rai G, Joshi N, Jung JE, Liu Y, Schultz L, Yasgar A et al. Potent and selective inhibitors of human reticulocyte 12/15-lipoxygenase as anti-stroke therapies. J Med Chem 2014; 57: 4035-4048.
51. Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol 2005; 1: 112-119.
52. Vanden Berghe T, Linkermann A, Jouan-Lanhouet S, Walczak H, Vandenabeele P. Regulated necrosis: the expanding network of non-apoptotic cell death pathways. Nat Rev Mol Cell Biol 2014; 15: 135-147.
53. Linkermann A, Skouta R, Himmerkus N, Mulay SR, Dewitz C, De Zen F et al. Synchronized renal tubular cell death involves ferroptosis. Proc Natl Acad Sci USA 2014; 111: 16836-16841.
54. Barnham KJ, Bush AI. Biological metals and metal-targeting compounds in major neurodegenerative diseases. Chem Soc Rev 2014; 43: 6727-6749.
55. Fisher M, Feuerstein G, Howells DW, Hurn PD, Kent TA, Savitz SI et al. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 2009; 40: 2244-2250.